---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-26-000029"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:18:43.780810+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q1 2026 revenue $139.1M (+21% YoY); GAAP net income $28.7M, adj. EBITDA $42.8M

## Summary
- Total revenue $139.1M (+21% YoY); testing revenue $135.1M (+26% YoY).
- GAAP net income $28.7M (20.6% of revenue); adjusted EBITDA $42.8M (30.8% of revenue).
- Decipher revenue $86.5M (+30%); Afirma revenue $46.4M (+21%).
- Testing volume 45,248 (+19%); Decipher tests ~28,000 (+24%), Afirma ~17,200 (+12%).
- Cash from operations $35.2M; cash & investments $439.1M; added Haas as CDTO and Ward as CHRO.

## SEC filing metadata
- accession: 0001384101-26-000029
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/0001384101-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/vcyt-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-26-000029
- JSON: https://secwatch.observer/filing/0001384101-26-000029.json
- Plain text: https://secwatch.observer/filing/0001384101-26-000029.txt

## Source-grounded claims
- claim_id: 84ed7ae8afe994102bdde20fcfe50488fd476b01
  claim: VERACYTE, INC. reported first quarter ended March 31, 2026 results: revenue $139.1 million, net income $28.7 million.
  evidence_excerpt: Key Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period in 2025: • Increased total revenue by 21% to $139.1 million and testing revenue by 26% to $135.1 million, driven by Decipher growth of 30% to $86.5 million and Afirma growth of 21% to $46.4 million. • Increased total volume by 17% to 47,615 tests and testing volume by 19% to 45,248 tests, driven by Decipher growth of 24% to approximately 28,000 tests and Afirma growth of 12% to approximately 17,200 tests. • Recorded GAAP net income of $28.7 million, or 20.6% of revenue, and delivered adjusted EBITDA of $42.8 million, or 30.8% of revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/0001384101-26-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.